PURPOSE: Genetic polymorphisms of cytokine-encoding genes are known to predispose to malignant disease. Interleukin (IL)-1 and IL-6 are crucially involved in breast carcinogenesis. Whether polymorphisms of the genes encoding IL-1 (IL1) and IL-6 (IL6) also influence breast cancer risk is unknown. EXPERIMENTAL DESIGN: In the present case-control study, we ascertained three polymorphisms of the IL1 gene cluster [-889 C/T polymorphism of the IL1alpha gene (IL1A), -511 C/T polymorphism of the IL1beta promoter (IL1B promoter), a polymorphism of IL1beta exon 5 (IL1B exon 5)], an 86-bp repeat in intron 2 of the IL1 receptor antagonist gene (IL1RN), and the -174 G/C polymorphism of the IL6 gene (IL6) in 269 patients with breast cancer and 227 healthy controls using PCR and pyrosequencing. RESULTS: Polymorphisms within the IL1 gene cluster and the respective haplotypes were not associated with the presence and the phenotype of breast cancer. The IL6 polymorphism was significantly associated with breast cancer. Odds ratios for women with one or two high-risk alleles versus women homozygous for the low-risk allele were 1.5 (95% confidence interval, 1.04-2.3; P = 0.04) and 2.0 (95% confidence interval, 1.1-3.6; P = 0.02), respectively. No association was ascertained between presence of the IL6 polymorphism and various clinicopathologic variables. CONCLUSIONS: Although polymorphisms within the IL1 gene cluster do not seem to influence breast cancer risk or phenotype, presence of the -174C IL6 allele increases the risk of breast cancer in Caucasian women in a dose-dependent fashion.
PURPOSE: Genetic polymorphisms of cytokine-encoding genes are known to predispose to malignant disease. Interleukin (IL)-1 and IL-6 are crucially involved in breast carcinogenesis. Whether polymorphisms of the genes encoding IL-1 (IL1) and IL-6 (IL6) also influence breast cancer risk is unknown. EXPERIMENTAL DESIGN: In the present case-control study, we ascertained three polymorphisms of the IL1 gene cluster [-889 C/T polymorphism of the IL1alpha gene (IL1A), -511 C/T polymorphism of the IL1beta promoter (IL1B promoter), a polymorphism of IL1beta exon 5 (IL1B exon 5)], an 86-bp repeat in intron 2 of the IL1 receptor antagonist gene (IL1RN), and the -174 G/C polymorphism of the IL6 gene (IL6) in 269 patients with breast cancer and 227 healthy controls using PCR and pyrosequencing. RESULTS: Polymorphisms within the IL1 gene cluster and the respective haplotypes were not associated with the presence and the phenotype of breast cancer. The IL6 polymorphism was significantly associated with breast cancer. Odds ratios for women with one or two high-risk alleles versus women homozygous for the low-risk allele were 1.5 (95% confidence interval, 1.04-2.3; P = 0.04) and 2.0 (95% confidence interval, 1.1-3.6; P = 0.02), respectively. No association was ascertained between presence of the IL6 polymorphism and various clinicopathologic variables. CONCLUSIONS: Although polymorphisms within the IL1 gene cluster do not seem to influence breast cancer risk or phenotype, presence of the -174C IL6 allele increases the risk of breast cancer in Caucasian women in a dose-dependent fashion.
Authors: A M González-Zuloeta Ladd; A Arias Vásquez; J Witteman; A G Uitterlinden; J W Coebergh; A Hofman; B H Ch Stricker; C M van Duijn Journal: Eur J Epidemiol Date: 2006-05-23 Impact factor: 8.082
Authors: Martha L Slattery; Jennifer S Herrick; Gabriella Torres-Mejia; Esther M John; Anna R Giuliano; Lisa M Hines; Mariana C Stern; Kathy B Baumgartner; Angela P Presson; Roger K Wolff Journal: Carcinogenesis Date: 2014-03-26 Impact factor: 4.944
Authors: Laure Dossus; Rudolf Kaaks; Federico Canzian; Demetrius Albanes; Sonja I Berndt; Heiner Boeing; Julie Buring; Stephen J Chanock; Francoise Clavel-Chapelon; Heather Spencer Feigelson; John M Gaziano; Edward Giovannucci; Carlos Gonzalez; Christopher A Haiman; Göran Hallmans; Susan E Hankinson; Richard B Hayes; Brian E Henderson; Robert N Hoover; David J Hunter; Kay-Tee Khaw; Laurence N Kolonel; Peter Kraft; Jing Ma; Loic Le Marchand; Eiliv Lund; Petra H M Peeters; Meir Stampfer; Dan O Stram; Gilles Thomas; Michael J Thun; Anne Tjonneland; Dimitrios Trichopoulos; Rosario Tumino; Elio Riboli; Jarmo Virtamo; Stephanie J Weinstein; Meredith Yeager; Regina G Ziegler; David G Cox Journal: Carcinogenesis Date: 2009-12-04 Impact factor: 4.944
Authors: Julienne E Bower; Patricia A Ganz; Michael R Irwin; Steven Castellon; Jesusa Arevalo; Steven W Cole Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: Alicia Collado-Hidalgo; Julienne E Bower; Patricia A Ganz; Michael R Irwin; Steve W Cole Journal: Brain Behav Immun Date: 2008-07-09 Impact factor: 7.217
Authors: Christoph Grimm; Eva Kantelhardt; Georg Heinze; Stephan Polterauer; Robert Zeillinger; Heinz Kölbl; Alexander Reinthaller; Lukas Hefler Journal: BMC Cancer Date: 2009-03-06 Impact factor: 4.430